Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: Exploration of biomarkers for treatment efficacy
Alimentary Pharmacology and Therapeutics Aug 21, 2017
Shao YY, et al. – The researchers investigated potential biomarkers of lenalidomide efficacy as second–line therapy for hepatocellular carcinoma (HCC). For advanced HCC, lenalidomide showed moderate activity as second–line therapy. Its immunomodulatory effects needed to be further explored
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
